
|Videos|April 20, 2023
The Use of Darolutamide in Patients with Castration-Resistant Prostate Cancer
Author(s)Matthew R. Smith, MD, PhD
Dr. Smith presents key data concerning the use of darolutamide in patients with castration-resistant CRPC, with a focus on safety and patient quality of life.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM
4
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
5






























